Immuron (IMRN) Struggles After Announcing Trial Results
Immuron Limited (NASDAQ:IMRN) is a biotechnology company that provides a medicine to prevent diarrhea and is also developing similar medicines.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 43,123 | $45,710 | +213% | 0% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,367 | $7,808 | 0% | |
| 2. | 5,200 | $5,512 | 0% | |
| 3. | 1,700 | $1,802 | 0% | |
| 4. | 363 | $385 | 0% | |
| 5. | 20,584 | $21 | 0% |